CU23837B1 - METAL CHELATES WITH PERFLUORATED RADICAL PEG - Google Patents

METAL CHELATES WITH PERFLUORATED RADICAL PEG

Info

Publication number
CU23837B1
CU23837B1 CU2009000059A CU20090059A CU23837B1 CU 23837 B1 CU23837 B1 CU 23837B1 CU 2009000059 A CU2009000059 A CU 2009000059A CU 20090059 A CU20090059 A CU 20090059A CU 23837 B1 CU23837 B1 CU 23837B1
Authority
CU
Cuba
Prior art keywords
metal chelates
perfluorated
radical
formula
peg
Prior art date
Application number
CU2009000059A
Other languages
Spanish (es)
Other versions
CU20090059A7 (en
Inventor
Heiko Schirmer
Hanns-Joachim Weinmann
Johannes Platzek
Ludwig Zorn
Bernd Misselwitz
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20090059A7 publication Critical patent/CU20090059A7/en
Publication of CU23837B1 publication Critical patent/CU23837B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se revelan quelatos con radical PEG perfluorado de fórmula I ESPACIO PARA LA FÓRMULA en especial aquellos ejemplificados y reivindicados,útiles para el diagnóstico NMR y por rayos-X, radiodiagnóstico y radioterapia y para linfografía MRT. Los quelatos metálicos con radical PEG encuentran aplicación en la tomografía por resonancia magnética nuclear (MRT) para la visualización de diferentes estructuras fisiológicas y con ello, para mejorar informaciones diagnósticas, específicamente la localización y el grado de la enfermedad, la selección y el control del éxito de una terapia puntual y para la profilaxis.Chelates with perfluorinated PEG radical of formula I SPACE FOR THE FORMULA are revealed, especially those exemplified and claimed, useful for NMR and X-ray diagnosis, radiodiagnosis and radiotherapy and for MRT lymphography. Metal chelates with PEG radical find application in nuclear magnetic resonance tomography (MRT) for the visualization of different physiological structures and with it, to improve diagnostic information, specifically the location and extent of the disease, the selection and control of success of a timely therapy and for prophylaxis.

CU2009000059A 2006-10-18 2009-04-17 METAL CHELATES WITH PERFLUORATED RADICAL PEG CU23837B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102006049821A DE102006049821A1 (en) 2006-10-18 2006-10-18 Metal chelates with perfluorinated PEG radical, process for their preparation, and their use
US85296306P 2006-10-20 2006-10-20
US89007107P 2007-02-15 2007-02-15
PCT/EP2007/007284 WO2008046463A1 (en) 2006-10-18 2007-08-11 Metal chelates having a perfluorinated peg group, method for the production thereof, and use thereof

Publications (2)

Publication Number Publication Date
CU20090059A7 CU20090059A7 (en) 2011-03-21
CU23837B1 true CU23837B1 (en) 2012-10-15

Family

ID=38670854

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2009000059A CU23837B1 (en) 2006-10-18 2009-04-17 METAL CHELATES WITH PERFLUORATED RADICAL PEG

Country Status (21)

Country Link
US (1) US8263040B2 (en)
EP (1) EP2089362A1 (en)
JP (1) JP5475454B2 (en)
KR (1) KR101451446B1 (en)
CN (1) CN101687803B (en)
AU (1) AU2007312691A1 (en)
BR (1) BRPI0717466A2 (en)
CA (1) CA2666910C (en)
CO (1) CO6170342A2 (en)
CR (1) CR10727A (en)
CU (1) CU23837B1 (en)
DE (1) DE102006049821A1 (en)
GT (1) GT200900087A (en)
IL (1) IL198173A0 (en)
MX (1) MX2009004097A (en)
MY (1) MY148553A (en)
NO (1) NO20091912L (en)
NZ (1) NZ576249A (en)
RU (1) RU2470014C2 (en)
SG (1) SG177994A1 (en)
WO (1) WO2008046463A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200536A1 (en) * 2007-08-13 2011-08-18 Harry John Wadsworth Chelators, paramagnetic chelates thereof and their use as contrast agents in magnetic resonance imaging (mri)
WO2017189967A1 (en) * 2016-04-29 2017-11-02 University Of Houston System Compositions, methods and kits for treating a contact lens
WO2019218339A1 (en) * 2018-05-16 2019-11-21 广州优尔材料科技有限公司 Silane compound containg perfluoropolyether group, preparation method therefor, surface treatment agent and product thereof
CN113677737B (en) 2019-03-29 2024-06-07 大金工业株式会社 Compound containing fluoropolyether group
CN121793988A (en) 2023-09-13 2026-04-03 东丽株式会社 Pharmaceutical composition for the treatment, prevention and/or diagnosis of cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588279A (en) * 1982-10-27 1986-05-13 Konishiroku Photo Industry Co., Ltd. Cleaning roller intermediate transfer member
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
EP0292306A3 (en) 1987-05-20 1989-09-13 Nippon Shokubai Co., Ltd. Methylolaminotriazine condensates and method for production thereof
US4838274A (en) 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
DE4008179A1 (en) * 1990-03-12 1991-09-19 Schering Ag FLUORBENZENE SULPHONAMIDE
US5250283A (en) 1990-03-28 1993-10-05 Molecular Biosystems, Inc. Organic contrast agent analog and method of making same
US5318770A (en) 1991-10-25 1994-06-07 Mallinckrodt Medical, Inc. Trifluoromethyl analogs of X-ray contrast media for magnetic resonance imaging
DE4203254C2 (en) 1992-02-05 1996-05-02 Max Planck Gesellschaft Fluorine-containing marker compound for NMR investigations and their use
US5482650A (en) * 1992-04-28 1996-01-09 Minnesota Mining And Manufacturing Company Liquid crystal compounds having perfluoroether terminal portions
US5756688A (en) * 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5401493A (en) 1993-03-26 1995-03-28 Molecular Biosystems, Inc. Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same
DE4317588C2 (en) * 1993-05-24 1998-04-16 Schering Ag Macrocyclic metal complexes containing fluorine, process for their preparation and their use
JPH0797340A (en) 1993-06-03 1995-04-11 Terumo Corp Mri contrast medium composition
US5502094A (en) 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5702637A (en) * 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
DE19603033A1 (en) * 1996-01-19 1997-07-24 Schering Ag Perfluoroalkyl-containing metal complexes, processes for their preparation and their use in NMR diagnostics
DE19729013A1 (en) * 1997-07-03 1999-02-04 Schering Ag Oligomeric, perfluoroalkyl-containing compounds, processes for their preparation and their use in NMR diagnostics
US6495118B1 (en) * 1997-09-26 2002-12-17 Schering Aktiengesellschaft Lipophilic metal complexes for necrosis and infarction imaging
DE19744003B4 (en) * 1997-09-26 2004-07-08 Schering Ag Contrast agent for infarct and necrosis imaging
DE19744004C1 (en) 1997-09-26 1999-07-22 Schering Ag Lipophilic metal complexes for necrosis and infarct imaging
AU742438C (en) 1997-10-02 2003-05-22 Lantheus Medical Imaging, Inc. Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
US6461587B1 (en) * 1999-03-22 2002-10-08 Schering Aktiengesellschaft Perfluoroalkylamides, their production and their use in diagnosis
DE19914101C1 (en) 1999-03-22 2000-10-12 Schering Ag Perfluoroalkylamides, their preparation and their use in diagnostics
DE19948651B4 (en) * 1999-09-29 2006-10-05 Schering Ag Galenic formulations containing para and diamagnetic perfluorinated compounds, their preparation and use
US6939329B1 (en) * 1999-10-08 2005-09-06 Harvest Technologies Corporation Apparatus for holding and operating one or more syringes
US6641797B2 (en) * 2000-08-11 2003-11-04 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
DE10066210B4 (en) 2000-08-11 2008-02-28 Bayer Schering Pharma Ag Use of perfluoroalkyl-containing metal complexes as contrast agents in MR imaging for plaque imaging
US6676928B2 (en) * 2000-08-11 2004-01-13 Schering Aktiengesellschaft Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use
DE10040381C1 (en) * 2000-08-11 2002-06-06 Schering Ag Perfluoroalkyl-containing complexes with sugar residues, process for their preparation and their use
DE10040858C2 (en) * 2000-08-11 2003-12-18 Schering Ag Perfluoroalkyl-containing complexes with polar residues, process for their preparation and their use
RU2206605C1 (en) * 2002-03-18 2003-06-20 Здоров Юрий Павлович Antiwear additives for lubrication media and fuel
WO2003086474A2 (en) * 2002-04-11 2003-10-23 Carbomer, Inc Fluorinated or paramagnetic alginate polymer, annexin paramagnetic conjugate, and their use as contrasting agent in mri
US7344704B2 (en) * 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
JP2004101881A (en) 2002-09-10 2004-04-02 Konica Minolta Holdings Inc Dry imaging material
CA2560544C (en) 2004-01-16 2015-05-19 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
RU2296756C2 (en) * 2005-05-17 2007-04-10 Федеральное унитарное государственное предприятие "Государственный научно-исследовательский институт биологического приборостроения" (ГосНИИ БП) Chelate-forming dibenzo-containing five-membered cyclic compounds comprising two symmetric beta-dicarbonyl substitutes with fluorinated radicals

Also Published As

Publication number Publication date
CN101687803B (en) 2012-05-30
MY148553A (en) 2013-04-30
CA2666910C (en) 2013-12-24
CR10727A (en) 2009-07-23
NO20091912L (en) 2009-07-17
CO6170342A2 (en) 2010-06-18
WO2008046463A1 (en) 2008-04-24
BRPI0717466A2 (en) 2014-04-15
DE102006049821A1 (en) 2008-04-24
JP2010506862A (en) 2010-03-04
HK1141526A1 (en) 2010-11-12
KR20090082222A (en) 2009-07-29
KR101451446B1 (en) 2014-10-16
CN101687803A (en) 2010-03-31
CU20090059A7 (en) 2011-03-21
US8263040B2 (en) 2012-09-11
US20080159954A1 (en) 2008-07-03
EP2089362A1 (en) 2009-08-19
GT200900087A (en) 2010-04-19
IL198173A0 (en) 2009-12-24
JP5475454B2 (en) 2014-04-16
RU2470014C2 (en) 2012-12-20
CA2666910A1 (en) 2008-04-24
NZ576249A (en) 2012-03-30
SG177994A1 (en) 2012-02-28
RU2009118486A (en) 2010-11-27
MX2009004097A (en) 2009-07-10
AU2007312691A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
Izadifar et al. Mechanical and biological effects of ultrasound: a review of present knowledge
CU23837B1 (en) METAL CHELATES WITH PERFLUORATED RADICAL PEG
JOP20230216A1 (en) A new contrast agent for use in magnetic resonance imaging (MRI).
Ali et al. MRI in necrotizing fasciitis of the extremities
ES2545959T3 (en) A medicine consisting of a derivative of carbostyril and donepezil for the treatment of Alzheimer's disease
BRPI0507684A (en) contrast agents for myocardial perfusion imaging
NZ710436A (en) Biospecific agents for bone
CL2025000135A1 (en) Fap-alpha specific tumor diagnostic imaging agent compound.
ATE411819T1 (en) CONJUGATES FOR MEDICAL IMAGING COMPRISING CARRIERS, TARGETING MOTIONS AND CONTRAST AGENTS
ECSP088100A (en) COMPLEXES WITH CONTENT OF PERFLUOROALQUILO, PROCEDURES FOR THEIR PREPARATION, AS WELL AS ITS USE
Munhoz et al. Diffusion-weighted magnetic resonance imaging in maxillary sinuses inflammatory diseases: report of three cases and literature review
TW200717360A (en) Quantifiable symmetry criterion method
ES2585558T3 (en) Use of 3-carboxy-N-ethyl-N, N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
Testempassi et al. Constrictive tuberculous pericarditis diagnosed using 18F-fluorodeoxyglucose positron emission tomography: a report of two cases
De Filippo et al. Benefits of 3D technique in guiding percutaneous retroperitoneal biopsies
RU2014125849A (en) Contrast agent for imaging myocardial perfusion
AR064232A1 (en) USE OF METALLIC COMPLEXES CONTAINING PERFLUOROALQUILO AS A CONTRAST MEASURE FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE
ITMO20100025U1 (en) MEDICAL DEVICE FOR THE USE OF AN ENDOSCOPIC INSTRUMENT FOR DIAGNOSTIC OR OPERATIONAL PURPOSE, PARTICULARLY IN UROLOGY AND GYNECOLOGY
Tamdy et al. Multiple mycotic aneurysms reveal Staphylococcus lugdunensis endocarditis in a young patient
Dirim et al. An unusual Hodgkin's lymphoma case presenting with upper extremity multiple masses
CN202198615U (en) Radiological examination bed
AR120033A1 (en) RADIOLABELED ANTAGONIST OF GRPR FOR USE AS A THERAPGNOSTIC AGENT
Dahine et al. Ultrasound findings in critical care patients: the “liver sign” and other abnormal abdominal air patterns
CN201602897U (en) Injection disinfection box special for magnetic resonance
Lee et al. Intracranial gossypiboma mimicking a recurrent low grade astrocytoma: case report

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)